Search PubMed⌕ Search

Biomedical subjects

B Chamontin

Publications and source records attributed to B Chamontin.

At least 37 records · Page 2Linked to original sources
PubMed1998

An attempt to improve blood pressure control in the French population: information and outcome awareness at the general practitioner level.

To improve blood pressure (BP) control in general practice, 3122 general practitioners agreed to participate in a result awareness program. A survey carried out 6 months after participating physicians had been informed of the outcome of treatments they had given showed that blood pressure control (cut-off point: BP < 140/90 mm Hg) had not improved. However, using less stringent criteria, a slight improvement in blood pressure control could be observed. Although this improvement was marginal, results are sufficiently encouraging to warrant another study after a new awareness campaign among the medical population.

Adult↗
PubMed1998

Ambulatory blood pressure and urinary albumin excretion in diabetic (non-insulin-dependent and insulin-dependent) hypertensive patients: relationships at baseline and after treatment by the angiotensin converting enzyme inhibitor trandolapril.

The aim of the present study was to examine the relationships between ambulatory blood pressure (ABPM) and urinary albumin excretion (UAE) in diabetic (non-insulin dependent [NIDDM] and insulin-dependent [IDDM]) hypertensives at baseline and after treatment by an angiotensin converting enzyme (ACE) inhibitor. After a 3-week placebo period, patients were treated for 16 weeks with trandolapril, 2 to 4 mg/day. The UAE and blood pressure (mercury sphygmomanometer and 24-h ABPM) were measured at baseline and repeated on trandolapril. Predictive factors of abnormal UAE (24-h UAE > or = 30 mg) were determined using univariate and multivariate analysis (logistic regression). Predictors of UAE decrease were also searched. One hundred seventy-one patients entered the analysis. Baseline office BP was 164+/-14 / 97+/-6 mm Hg and 24-h BP was 142+/-17 / 83+/-10 mm Hg. Seventy-four patients (43%) had UAE > or = 30 mg. Independent risk factors for abnormal UAE were nighttime diastolic BP (odds ratio [OR] = 4.1, confidence interval [CI] = 2.0 to 8.6, P = .0001), diabetes duration (OR = 2.4, CI = 1.1 to 5.0, P = .025), and presence of retinopathy (OR = 3.2, CI = 1.0 to 10.0, P = .047). Conversely, office BP level was not significantly related to UAE. On treatment, office BP levels decreased to 143+/-13 / 82+/-8 mm Hg (P < .0001) and 24-h BP levels to 134+/-17 / 78+/-9 mm Hg (P < .0001). In the abnormal UAE group, UAE significantly decreased from 76 to 50 mg/day (P = .006). After treatment, independent predictive factors of abnormal UAE were: on-drug fasting plasma glucose (OR = 3.5, CI = 1.7 to 7.4, P = .0009) and on-drug nighttime diastolic BP (OR = 3.5, CI = 1.7 to 7.4, P = .001). The only predictor of UAE decrease was a 24-h systolic BP decrease (OR = 2.3, CI = 1.3 to 4.3, P = .007). We conclude that in diabetic hypertensives with abnormal UAE, trandolapril exhibited a sustained 24-h antihypertensive effect and provided a consistent reduction of microalbuminuria. This study confirmed the superiority of ABPM over clinical BP to predict target organ damage.

Albuminuria↗
PubMed1998

[Ambulatory blood pressure, intima media thickness, global cardiovascular risk and therapeutic decisions].

OBJECTIVE: To determine the influence of ambulatory blood pressure monitoring (ABPM), carotid intima media thickness (IMT) and global cardiovascular risk on the therapeutic strategies issued from our hypertension unit. METHODS: All essential uncomplicated and never treated hypertensive patients referred to our hypertension unit between 1996 and 1997 for etiologic or target organ damage evaluation were considered eligible. We excluded diabetics and patients with renal disease who need a specific therapeutical approach. 54 patients (44.7 +/- 10.1 years) were included (40 men). All patients underwent an ABPM measurement. The right common carotid IMT measurement had been performed (0.06 +/- 09 mm). The global cardiovascular risks were assessed with the Framingham prediction chart taking into account age, sex, total cholesterol, smoking status and systolic office blood pressure. According to the therapeutic decision three groups were made up: group 1 lifestyle counselling (n = 13), group 2 single drug therapy (n = 31), and group 3 combination therapy (n = 10). RESULTS: No significant difference was found in age, sex ratio, prevalence of severe hypertension, office systolic blood pressure, body mass index, global cardiovascular risk between the three groups. In contrast ABP (24 h ABP mmHg: group 1: 128.23 +/- 6.91/79.7 +/- 6.4; group 2: 140.48 +/- 9.7/97.48 +/- 8.17; group 3: 152.4 +/- 15.35/99.4 +/- 12.14 p < .0001) and IMT (group 1: 10.55 +/- .09, group 2: .59 +/- .07, group 3: .66 +/- .11 p = .02), were significantly higher in group 3 than in group 2 and in group 1. The percentage of white coat hypertensives was higher in group 1 than in group 3 (group 1: 61.5%, group 2: 3.2%, group 3: 0%). In the whole population, the higher was the global cardiovascular risk, the higher was the common carotid intima media thickness. In this study the global cardiovascular risks are not related to therapeutic decisions. Therapeutic strategies are influenced by ABP level and by the vascular remodeling which depends partly on the global cardiovascular risk.

Adult↗
PubMed1998

[Influence of global cardiovascular risk assessment on the management of hypertension in southwestern France].

1,160 subjects aged 35-64 years were recruited by the Haute-Garonne MONICA center, and selected by stratified randomization on age and size of home area. The hypertensive group included: 176 subjects newly diagnosed as hypertensives (blood pressure > or = 140/90 mmHg), 86 known but untreated hypertensives and 178 hypertensives under treatment. For each subject a score of coronary heart disease risk based on the Framingham point score probability algorithm was calculated. The prevalence of hypertension was 37.9%. Among the 440 subjects considered as hypertensives, 60% were aware of having hypertension. Only 30% of the 178 patients treated achieved blood pressure control. The population as a whole was at low coronary heart disease risk (< 5% at 10 years); the groups at higher risk were newly diagnosed hypertensives and treated hypertensives. Among known hypertensives, the risk level was higher in treated compared with untreated. In this survey 1) the prevalence of hypertension was high; 2) only 30% of treated hypertensives were below 140/90 mmHg; 3) usual care failed to recognize 40% of hypertensives at same risk level as treated ones; 4) treated hypertensives had higher coronary heart disease risk than untreated known hypertensives. The hypertension therapeutic strategy could be based on the reduction of blood pressure below the threshold 140/90 mmHg rather than on the absolute cardiovascular risk.

Adult↗
PubMed1997

Influence of nycthemeral blood pressure pattern in treated hypertensive patients on hemodialysis.

Arterial hypertension in end-stage renal disease (ESRD) patients is characterized by an altered nycthemeral blood pressure (BP) rhythm and an increased pulse pressure, and it could be suggested that this association of risk factors plays a major role in the cardiovascular prognosis of this population. The aim of this study was to determine the influence of nycthemeral BP pattern on arterial distensibility and pulsatile components of BP in treated hypertensive patients on regular hemodialysis. Forty-two hypertensive patients were included, and all underwent ambulatory BP and pulse wave velocity (PWV) measurements between the femoral and carotid arteries. The patients were divided into two groups according to the magnitude of the nocturnal fall in BP: dippers and non-dippers. The groups were similar in gender, age, duration of hemodialysis, body mass index, body size, history of cardiovascular complications, class and number of antihypertensive drugs used per patient. PWV was significantly higher in non-dippers. For the whole population, a stepwise regression analysis showed that PWV and erythropoietin therapy were independently related to the impaired nycthemeral BP pattern. In addition to its pressor effect, erythropoietin could have a deleterious influence on the ambulatory BP profile of treated hypertensive patients in ESRD. Arterial distensibility and nycthemeral BP impairment are linked, and these cardiovascular risk factors should be taken into account together for the management of hypertensive hemodialysis patients.

Adult↗
PubMed1997

[Intima media thickness of the carotid artery in white coat and ambulatory hypertension].

Recent epidemiological studies have reported an association between carotid intima media thickness (IMT), ambulatory blood pressure (ABP) and absolute cardiovascular risk. To study the relation between white coat effect and vascular changes in hypertensives (HT), 57 essential HT (office blood pressure (OBP) 152.2 +/- 19.5/93.7 +/- 12.4 mmHg) were recruited (46.4 +/- 11.8 years old, 49 men). After antihypertensive drugs withdrawal, an ABP was performed (Spacelabs 90207). The right common carotid artery IMT 3 cm proximal to the bifurcation was examined by ultrasonography. IMT (0.59 +/- 0.09 mm; Software lotec system) were measured by a reader blinded to the ABP data. White coat hypertension (WCH) was defined by a mean day-time ambulatory BP (d-ABP) lower than the 90th percentile of the distribution of daytime ABP of a normotensive population reported by Verdecchia et al. (131/86 mmHg in women and 136/87 mmHg in men). [table: see text] White coat hypertension was found in 8 from 57 (14%) subjects. IMT was significantly increased in ambulatory HT when compared with white coat HT while age, sex ratio, OBP, smoking status were not different. In stepwise regression age and systolic d-ABP were the only determinants of IMT (p < 0.05). In our hypertensive population. ABP appears more closely related to IMT than OBP and IMT in sustained is greater than in white coat hypertensive.

Adult↗
PubMed1996

Twenty-four-hour ambulatory blood pressure monitoring in the evaluation of antihypertensive drugs: methodological aspects.

Ambulatory blood pressure monitoring (ABPM) provides reproducible measurements over 24 h, avoiding the alerting reaction. However, the reproducibility of mean hourly ambulatory values is poorer by far than the whole day average. In phases II and III clinical triams ABPM seems to evaluate the time-course of the antihypertensive effect and helps to determine the trough: peak ratio. The potential advantage of the method could be an increase in statistical power of the trial, with regard to the number of patients to include, according to the study design. ABPM led to the identification of 'white-coat' hypertension with elevated clinic blood pressure measurements and persistently normal ABPM over time. No epidemiological evidence to include patients in trials according to ABPM criteria has been provided to date, but a subsequent stratification on the initial ABPM data has to be performed. Although an insignificant effect on the 24 h mean blood pressure values in short-term trials, the use of placebo seems to be necessary to supply reference blood pressure values for dosing and trough: peak ratio determination. Whether ABPM is able to decrease the number of patients to include remains debated. It has been noted that an increasing number of readings could lead to a decrease in SD and that a decrease in the number of patients required can be expected both in parallel and in cross-over design trials. However, it has been reported that the advantage of the higher reproducibility of ABPM could be lost in parallel design trials and that analysis of the antihypertensive effect of the drug throughout the 24 h could then require more patients. In order to conduct multicentre trials using ABPM, a consensus among investigators is needed for the presentation and analysis of the results. We have to overcome these difficulties in order to avoid a 'centre effect' and to allow for the expected increase in power of the trial. In such a trial the comparability of parallel groups could be jeopardized by a misadherence to the ABPM protocol. How can ABPM modify the doctor-patient relationship?. A pedagogical approach seems necessary, namely to inform the patients concerning technical and medical prerequisites of the method, in order to conform to the 'guidelines'. ABPM might constitute a new determinant of compliance with treatment; but its influence, beneficial or not, remains to be assessed. Compliance evaluation could be combined with ABPM, in order to provide a better evaluation of the antihypertensive effect of the drugs.

Journal Article↗
PubMed1996

Dippers and non-dippers among overweight hypertensive men.

OBJECTIVE: To determine the links between circadian blood pressure rhythm and metabolic profile in overweight essential hypertensive men with an elevated waist: hip ratio (> 0.95). METHODS: Ambulatory blood pressure monitoring (ABPM) was performed in 53 patients (using a SpaceLabs 90207 device) after withdrawal of antihypertensive medication. All of the patients underwent an oral glucose-tolerance test. Blood lipids and lipoproteins were measured with standard techniques. The left ventricular mass index was determined by echocardiography according to American Society of Echocardiography (ASE) recommendations. According to the magnitude of the decrease in nocturnal blood pressure measured by ABPM two groups were defined: dippers (n = 27) and non-dippers (n = 26). RESULTS: The non-dipper group showed a higher diurnal and noctural pulse pressure, a greater left ventricular mass index and a higher level of 2 h glycaemia, in spite of their body mass index being almost identical to that of the dipper group. There were no differences in lipid parameters. In stepwise regression analysis, age and 2 h glycaemia appeared to be the only independent determinants of an altered circadian blood pressure pattern. In order to specify the potential influence of the metabolic profile independently of age on the circadian blood pressure pattern, two age-matched subgroups were constituted. Of the 53 hypertensive patients, 28 from the dipper and non-dipper groups were considered; for each non-dipper patient an age-matched (within 2 years) dipper patient was selected from the population. Despite their having the same age, body mass index and fasting glycaemia, a higher 2 h glycaemia (P < 0.01) and, to a lesser extent, a higher 3 h glycaemia (P = 0.06) were observed in the non-dipper group compared with the dipper group. CONCLUSION: It is suggested that, in overweight hypertensive men, a reduced nocturnal blood pressure decrease could be related both to age and to metabolic profile and that ABPM could be an effective tool for a global approach to cardiovascular risk in this population.

Journal Article↗
PubMed1996

Relationships between blood pressure components, lipids and lipoproteins in normotensive men.

The aim of this study is to assess the relationships between pulse pressure (PP) mean arterial pressure (MAP), clinical and lipid parameters in normotensive men. One hundred and twenty-seven normotensive men aged 35-64 years from the French department of Haute-Garonne were analysed. Blood pressure (BP) was measured using a random zero device. Correlation analysis was performed using Pearson's coefficient. Variables significantly related to PP and MAP were then introduced in a stepwise multiple regression analysis. On univariate analysis, PP was significantly and positively related to total cholesterol, triglycerides, VLDL and LDL-cholesterol and apo B. MAP was positively related to age, body mass index (BMI), triglycerides and VLDL-cholesterol. Stepwise multiple regression analysis showed only apo B to be independently related to PP after adjustment for MAP. Also, after adjustment for PP, only BMI and VLDL-cholesterol were related to MAP. Hence, MAP is related to BMI and VLDL-cholesterol, which are a common feature of hyperinsulinism. PP is linked to apo B, an important proatherogenic factor. These biological parameters appear specific of steady and pulsatile components of BP. The relationship between PP and apo B suggests a possible link between lipids and arterial stiffness, and may partly explain the prognostic value of PP in myocardial infarction.

Adult↗
PubMed1996

[Aldosterone precursors and hypertension with hypokalemia and adrenal module non caused by primary hyperaldosteronism].

The purpose of the study was to evaluate the interest of aldosterone precursors assays in arterial hypertension with hypokaliemia and adrenal nodules non due to aldosterone. Seven hypertensive patients, 3 men and 4 women, aged 59.5 +/- 10.1 years were included in the study. After drug withdrawal, kaliemia was 3.1 +/- 0.3 mmol/l (2.7-3.6), active renin 2.9 +/- 1.4 ng/l, plasma aldosterone (aldo) 108 +/- 49.4 pg/ml, cortisol 13 +/- 3.1 micrograms/100 ml, and [S] 0.47 +/- 0.5 micrograms/100 ml. Adrenal CT scan showed an adenoma in 3 patients (30.5 +/- 5 mm) and an unilateral nodular hyperplasia in 4 patients. In all patients, the plasma levels (RIA, chomatographic step) of the following steroids in the mineralocorticoid (MC) pathway were determined: DOC, 18 OH-DOC, B, 18 OH-B and aldosterone. Two from 7 (28%) exerted aldosterone precursors excess, 1 with DOC-producing adenoma (DOC-PA) (table), and 1 with a partial 11 beta hydroxylase deficiency (DOC: 211 pg/ml; S: 1 mu/100 ml). Aldosterone/DOC + 18 OH-DOC ratio proposed as a malignancy index was decreased in the patient with DOC-PA (8.1). No dysfunction in the MC pathway was identified in the 5 other patients. [table: see text] The study suggests the relevance of aldosterone precursors assays in low renin hypertension non due to aldosterone and in incidentally discovered adrenal masses.

Adenoma↗
PubMed1996

[Prevalence, treatment and control of hypertension in family practice patients in France during 1994].

The aim of this study was to measure the percentage of patients with hypertension, treated hypertension and controlled hypertension, using data collected over one week by 235 general practitioners well representative of the French medical population and selected by SOFRES Médical. Practitioners had to carry out their own survey over a period of one week on all patients above 18 years of age who visited their office. They were initially instructed to use the same type of mercury sphygmomanometer, equiped with the same pneumatic cuffs of different sizes. Three consecutive blood pressure measurements were effected, the last two were recorded. Patients were considered as hypertensive if the mean of the two recorded BP measurements was > or = 140-90 mmHg, or < 140-90 mmHg under pharmacological treatment. Hypertensive patients were considered as controlled when their blood pressure levels were overall < 140-90 mmHg under treatment. According to age, two other control levels were analysed: blood pressure < 160-95 mmHg before 65 years and blood pressure < 160-90 mmHg at 65 years or more. Among 12,351 patients, 5,020 are hypertensive (4%), 2,985 under pharmacological treatment (59%) and 2,035 without treatment (4%). Among untreated patients, 9% had an hypertension above the borderline values. Before 65 years, 28% had an under treatment blood pressure < 140-90 mmHg and 71% < 160-95 mmHg. Among 65 years or more hypertensive patients, 21% had an under treatment blood pressure < 140-90 mmHg and 60% < 160-90 mmHg. Before 65 years, 25% among patients with a monotherapy remained with a blood pressure > 160-95 mmHg and 34% with a blood pressure > 160-90 mmHg among those of 65 years or more; 230 patients (5%) remained in high risk with a blood pressure > 180-105 mmHg. 176 untreated and 54 despite their treatment. This study carried out in French medical practice yield two main conclusions regarding the management of hypertension: as the prevalence of hypertensive patients is 41%: one patient out of two, high blood pressure has to be a main aim for the medical teaching. Even if a reasonable control of the blood pressure is achieved in most cases, blood pressure got a normal level for 24% only of treated hypertensive patients and too many patients were keeping high risk because they have been not or not enough treated. This study, as a real audit, gives some useful informations to general practitioners in order to improve their scores.

Adolescent↗
PubMed1996

[Course of ischemic risk in treated atheromatous hypertensive patients. The PRIHAM study (Prognosis of Ischemic Risk in Atheromatous Patients under Mediatensyl)].

Hypertension is one of the major cardiovascular risk factors. However it seldom occurs alone in a patient and the antihypertensive treatment should be taken into account when assessing global cardiovascular status. The PRIHAM study was an open study which enrolled 3,216 hypertensive atheromatous patients who already has had a clinical ischaemic accident. Patients were followed-up for 3 years. The lowering effect on cardiovascular risk, starting from the fifteenth month was confirmed to the end of 36-month study. The effect on blood pressure was observed from the third month. Stabilized blood pressure observed within the first year persisted throughout the three years without tachyphylaxis. It was effective on SBP (-14.4%) and on DBP (-15%) while maintaining a stable heart rate both in the supine position or immediately upon standing or after 3 minutes in the standing position. Tolerance was globally judged as good or very good by the investigating practitioners and the patients expressed an improvement in their feeling of well-being. In conclusion, from the level of effectiveness obtained and the low incidence of adverse effects, urapidil appears well adapted and easy to manage in a population with a particularly high cardiovascular risk.

Adult↗
PubMed1995

Influence of glucose metabolism on nycthemeral blood pressure variability in hypertensives with an elevated waist-hip ratio. A link with arterial distensibility.

We studied the influence of glucose metabolism on the nycthemeral blood pressure (BP) pattern and arterial distensibility in 33 nontreated hypertensive patients, 45.6 +/- 8.5 years old, with elevated waist/hip ratio. All patients underwent an ambulatory BP monitoring, a pulse wave velocity (PWV) measurement, and an oral glucose tolerance test. The ratio of mean nocturnal:diurnal systolic BP (N/D ratio) was used to assess nycthemeral BP variability. N/D ratio correlated positively with PWV (r = 0.62; P < .01). When considered according to their glycemic status, N/D ratio and PWV were significantly higher (P < .05; P < .01) in diabetics and in glucose intolerants compared to patients with normal glucose levels. Our data indicate that the nycthemeral BP pattern was different according to the metabolic status. The loss of nocturnal decline in BP is associated with carbohydrate disturbances and reduced arterial stiffness.

Adult↗
PubMed1995

Plasma levels of aldosterone versus aldosterone precursors: a way to estimate the malignancy of asymptomatic and nonsecretory adrenal tumors: a French Retrospective Multicentric Study.

The aim of this study was to find out whether the dysfunction of aldosterone pathway, previously proposed as a marker of secretory adrenal carcinoma, is also found in nonsecretory adrenal carcinomas, which pose even more difficult diagnostic problems even for patients with hypertension accompanied or not by hypokalemia. The exploration consisted of using the same method (RIA preceded by a chromatographic step) to determine the plasma levels of the following steroids in the mineral corticosteroid pathway: deoxycorticosterone (DOC), 18-hydroxydeoxycorticosterone (18-OHDOC), corticosterone (B), 18 hydroxycorticosterone (18 OH B), and aldosterone. The subjects included 16 adults, each presenting with an endocrinologically asymptomatic adrenal mass associated for some patients with hypokalemia and hypertension (8 with adrenal carcinoma, 2 with adrenal metastasis from other forms of cancer, and 6 adenomas). These results show that even in nonsecretory adrenal carcinoma, there is a dysfunction of the aldosterone pathway, which can be evaluated from the ratio between aldosterone and the substrate of 11 beta hydroxylase (DOC) and its derivative (18-OH DOC). This study suggests that exploration of mineralocorticosteroid pathway can be used as a hormonal marker of adrenal carcinoma for both secretory and non-secretory malignant masses.

Adrenal Gland Neoplasms↗
PubMed1995

[Conceptual basis and diagnosis of primary hyperaldosteronism].

Primary aldosteronism comprises two different conditions, the tumoral form usually caused by an adenoma and the idiopathic form due to nodular hyperplasia of the two adenals. More rarely, an adenoma of the adrenal cortex, glucocorticosteroid-sensitive hyperplasia, and angiotensin-sensitive adenoma or an autonomous nodule transformed to primary tumoral hyperplasia, may be observed. Primary alderosteronism may be conceived as a spectrum of genetic abnormalities which express themselves either by hyperplasia or by a tumour. A defect in steroid genesis and prolonged stimulation of the cortex would lead to the formation of nodules which may become autonomous and generate a tumour. Hypertension may be isolated. Detection requires three sampling of serum potassium in all hypertensive patients, a study of the aldosterone-renin axis when the value is less than 3.6 mEq, or whenever the hypertension is severe or resistant to treatment. The diagnosis is made by the association of an increased plasma aldosterone level before getting up in the morning and a plasma renin unaffected by orthostatism. The choice of medical or surgical treatment depends on the uni- or bilateral anatomic substrate. Computerised tomography, very sensitive but not specific, like hormonal studies, often provides incomplete answers. Adrenalectomy is indicated in the presence of a mass of centimetric proportions with concordant results of the dynamic test. In other situations, investigations are continued with the search for an aldosterone gradient by selective venous sampling. This is very valuable to determine the lateralisation but fails in 25% of cases, and its results have to be compared with those of imaging techniques: CT scan, venography and, when necessary, scintigraphy.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenoma↗
PubMed1995

[Combination therapy in the therapeutic strategy of arterial hypertension].

The standard treatment of mild-to-moderate hypertension is monotherapy chosen from one of the five main classes of antihypertensives following the World Health Organisation and Joint National Committee guidelines. If first-line monotherapy fails, the physician must decide whether to increase the dose, choose a drug from a different class or add a second antihypertensive. However, greater efficacy must not be obtained at the cost of an unacceptable increase in side-effects. Sequential monotherapy is partly based on the impossibility of predicting the blood pressure response to a given antihypertensive. The validity of this strategy is supported by the findings of the Materson study, which suggest combination therapy only after the failure of at least two monotherapies. The aim of combination therapy is to optimize treatment by using two different classes of antihypertensives with synergistic effects. The anticipated advantages are ease of use, the enhancement or addition of the antihypertensive effects, and the possibility of administration to a wide population. This has led to the development of fixed combinations which are low-dosed to reduce the incidence of side-effects. Validated combinations (dosed differently according to the medicinal product) include: beta-blocker + diuretic, beta-blocker + dihydropyridine (DHP) calcium antagonist, angiotensin converting enzyme (ACE)-inhibitor + diuretic and in the future, ACE-inhibitor + calcium antagonist. The pharmacokinetic interaction of beta-blocker + DHP at the hepatic level must be considered to assess the efficacy of this combination.(ABSTRACT TRUNCATED AT 250 WORDS)

Antihypertensive Agents↗